X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26) Misses $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals (NASDAQ:XFOR) reported a Q1 2024 GAAP EPS loss of $(0.26), missing the $(0.16) analyst consensus estimate by 62.5%. This represents a 62.5% increase in losses compared to the same period last year.
May 07, 2024 | 10:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
X4 Pharmaceuticals reported a larger than expected loss for Q1 2024, with EPS of $(0.26) missing estimates by 62.5%.
The reported earnings miss is likely to negatively impact investor sentiment in the short term, as the actual losses were significantly higher than what analysts expected. This could lead to a decrease in stock price as investors adjust their expectations based on the new financial performance data.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100